{"id":52206,"date":"2025-12-29T21:20:14","date_gmt":"2025-12-29T13:20:14","guid":{"rendered":"https:\/\/flcube.com\/?p=52206"},"modified":"2025-12-30T21:03:19","modified_gmt":"2025-12-30T13:03:19","slug":"hansoh-pharma-licenses-hengruis-shr6508-for-rmb-220-million-to-expand-renal-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52206","title":{"rendered":"Hansoh Pharma Licenses Hengrui&#8217;s SHR6508 for RMB 220 Million to Expand Renal Portfolio"},"content":{"rendered":"\n<p><strong>Hansoh Pharmaceutical Group Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced a <strong>licensing agreement<\/strong> with <strong>Jiangsu Hengrui Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) to obtain <strong>exclusive rights<\/strong> for <strong>SHR6508<\/strong>, a <strong>Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator<\/strong>, in <strong>Mainland China<\/strong> for the treatment of <strong>secondary hyperparathyroidism (SHPT)<\/strong> in chronic kidney disease (CKD) patients on hemodialysis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Jiangsu Hengrui Pharmaceutical (600276.SH\/1276.HK)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Hansoh Pharmaceutical Group (3692.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SHR6508 (allosteric CaSR modulator)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (excludes Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Development, manufacturing, commercialization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>SHPT in adult CKD patients undergoing hemodialysis<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase\u202fIII trials ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>RMB 30\u202fmillion<\/strong> (~US$4.2\u202fM)<\/td><td>Paid upon agreement execution<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td><strong>Up to RMB 190\u202fmillion<\/strong><\/td><td>Regulatory &amp; commercialization milestones<\/td><\/tr><tr><td><strong>Royalty Rates<\/strong><\/td><td><strong>Tiered single\u2011digit %<\/strong><\/td><td>On net sales; scales with revenue volume<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>Up to RMB 220\u202fmillion<\/strong><\/td><td>Excludes royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-shr6508\">Product Profile: SHR6508<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>: <strong>Allosteric modulator of calcium\u2011sensing receptor (CaSR)<\/strong> that increases receptor sensitivity to extracellular calcium, thereby <strong>reducing parathyroid hormone (PTH)<\/strong> secretion.<\/p>\n\n\n\n<p><strong>Key Differentiation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral administration<\/strong> (vs. IV alternatives like etelcalcetide)<\/li>\n\n\n\n<li><strong>Potential for improved safety profile<\/strong> vs. first\u2011generation calcimimetics<\/li>\n\n\n\n<li><strong>Complementary to Hansoh\u2019s renal portfolio<\/strong> (existing phosphate binders, vitamin D analogs)<\/li>\n<\/ul>\n\n\n\n<p><strong>Development Status<\/strong>: Currently in <strong>Phase\u202fIII trials<\/strong> in China; pivotal data expected <strong>H2\u202f2026<\/strong> supporting NDA filing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>China CKD &amp; SHPT Landscape<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD Prevalence<\/strong>: <strong>~130\u202fmillion<\/strong> patients in China; <strong>~500,000<\/strong> on hemodialysis (2025)<\/li>\n\n\n\n<li><strong>SHPT Incidence<\/strong>: <strong>30\u201150%<\/strong> of dialysis patients develop SHPT \u2192 <strong>150,000\u2011250,000<\/strong> eligible patients<\/li>\n\n\n\n<li><strong>Current Treatations<\/strong>: Generic cinacalcet (Amgen\u2019s Sensipar), IV etelcalcetide, vitamin D analogs, phosphate binders<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China SHPT drug market valued at <strong>\u00a52.8\u202fbillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong> driven by dialysis population expansion<\/li>\n<\/ul>\n\n\n\n<p><strong>Unmet Need<\/strong>: <strong>15\u201120%<\/strong> of patients are refractory or intolerant to existing therapies; SHR6508 targets this underserved segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>Portfolio Synergy<\/strong>: SHR6508 strengthens Hansoh\u2019s <strong>renal disease franchise<\/strong>, creating a <strong>comprehensive CKD\u2011SHPT offering<\/strong> alongside its marketed phosphate binders and vitamin D products.<\/p>\n\n\n\n<p><strong>Commercial Leverage<\/strong>: Hansoh\u2019s established <strong>nephrology sales force<\/strong> (covering 800+ dialysis centers) can rapidly commercialize SHR6508 upon approval, reducing launch costs and accelerating market penetration.<\/p>\n\n\n\n<p><strong>Financial Upside<\/strong>: If approved, SHR6508 could generate <strong>peak sales of \u00a5500\u2011700\u202fmillion<\/strong> (US$70\u201198\u202fM) by 2030, assuming <strong>20\u201125% market share<\/strong> in the SHPT segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Route<\/th><th>Stage (China)<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Cinacalcet (generic)<\/strong><\/td><td>Various<\/td><td>CaSR agonist<\/td><td>Oral<\/td><td>Marketed<\/td><td>\u00a58,000\u201112,000<\/td><\/tr><tr><td><strong>Etelcalcetide<\/strong><\/td><td>Kyowa Kirin<\/td><td>CaSR agonist<\/td><td>IV<\/td><td>Marketed<\/td><td>\u00a525,000\u201130,000<\/td><\/tr><tr><td><strong>SHR6508<\/strong><\/td><td><strong>Hengrui \u2192 Hansoh<\/strong><\/td><td>CaSR allosteric modulator<\/td><td>Oral<\/td><td>Phase\u202fIII<\/td><td>TBD (expected \u00a515,000\u201120,000)<\/td><\/tr><tr><td><strong>Evadaxistat<\/strong><\/td><td>AstraZeneca<\/td><td>HIF\u2011PH inhibitor<\/td><td>Oral<\/td><td>Phase\u202fII<\/td><td>Not applicable for SHPT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: SHR6508\u2019s <strong>allosteric modulation<\/strong> may offer <strong>better tolerability<\/strong> vs. orthosteric cinacalcet, while oral dosing improves <strong>patient compliance<\/strong> vs. IV etelcalcetide.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SHR6508\u2019s clinical development timeline, regulatory approval probability, peak sales forecasts, and market penetration assumptions. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, pricing negotiations, and NRDL reimbursement decisions.<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025122800302_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025122800302_c.\"><\/object><a id=\"wp-block-file--media-954ea47f-5467-41a0-bda8-914c1253f244\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025122800302_c.pdf\">2025122800302_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025122800302_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-954ea47f-5467-41a0-bda8-914c1253f244\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[363,2586,4228,1182,852],"class_list":["post-52206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hansoh-pharmaceutical","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-hkg-3692","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharma Licenses Hengrui&#039;s SHR6508 for RMB 220 Million to Expand Renal Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) to obtain exclusive rights for SHR6508, a Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator, in Mainland China for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on hemodialysis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52206\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharma Licenses Hengrui&#039;s SHR6508 for RMB 220 Million to Expand Renal Portfolio\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) to obtain exclusive rights for SHR6508, a Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator, in Mainland China for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on hemodialysis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52206\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T13:20:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T13:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharma Licenses Hengrui&#8217;s SHR6508 for RMB 220 Million to Expand Renal Portfolio\",\"datePublished\":\"2025-12-29T13:20:14+00:00\",\"dateModified\":\"2025-12-30T13:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206\"},\"wordCount\":486,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2907.webp\",\"keywords\":[\"Hansoh Pharmaceutical\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"HKG: 3692\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52206#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52206\",\"name\":\"Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2907.webp\",\"datePublished\":\"2025-12-29T13:20:14+00:00\",\"dateModified\":\"2025-12-30T13:03:19+00:00\",\"description\":\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) to obtain exclusive rights for SHR6508, a Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator, in Mainland China for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on hemodialysis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52206\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2907.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52206#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharma Licenses Hengrui&#8217;s SHR6508 for RMB 220 Million to Expand Renal Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) to obtain exclusive rights for SHR6508, a Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator, in Mainland China for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on hemodialysis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52206","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio","og_description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) to obtain exclusive rights for SHR6508, a Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator, in Mainland China for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on hemodialysis.","og_url":"https:\/\/flcube.com\/?p=52206","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T13:20:14+00:00","article_modified_time":"2025-12-30T13:03:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52206#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52206"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharma Licenses Hengrui&#8217;s SHR6508 for RMB 220 Million to Expand Renal Portfolio","datePublished":"2025-12-29T13:20:14+00:00","dateModified":"2025-12-30T13:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52206"},"wordCount":486,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52206#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp","keywords":["Hansoh Pharmaceutical","Hengrui Pharmaceuticals","HKG: 1276","HKG: 3692","SHA: 600276"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52206#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52206","url":"https:\/\/flcube.com\/?p=52206","name":"Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52206#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52206#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp","datePublished":"2025-12-29T13:20:14+00:00","dateModified":"2025-12-30T13:03:19+00:00","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) to obtain exclusive rights for SHR6508, a Phase\u202fIII calcium\u2011sensing receptor (CaSR) modulator, in Mainland China for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on hemodialysis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52206#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52206"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52206#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp","width":1080,"height":608,"caption":"Hansoh Pharma Licenses Hengrui's SHR6508 for RMB 220 Million to Expand Renal Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52206#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharma Licenses Hengrui&#8217;s SHR6508 for RMB 220 Million to Expand Renal Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52206"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52206\/revisions"}],"predecessor-version":[{"id":52209,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52206\/revisions\/52209"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52208"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}